A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus

Inclusion Criteria:

• have type 1 diabetes mellitus (T1DM) based on the disease diagnostic criteria
• have had a duration of diabetes ≥1 year
• have hemoglobin A1c ≤10.0%
• have fasting C-peptide ≤0.3 nanomoles per liter (nmol/L)
• have a body mass index ≤29 kilograms per square meter (kg/m²)
• have venous access sufficient to allow blood sampling and cannulation for clamp procedures

Exclusion Criteria:

• are currently enrolled in, have completed, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device
• have a total insulin requirement >1.2 units per kilogram per day (U/kg/day)
• have a history of proliferative retinopathy
• have known allergies to insulin glargine, insulin lispro, heparin, or related compounds
• have an electrocardiogram (ECG) reading considered outside the normal limits
• have an abnormal blood pressure
• have abnormal clinical laboratory tests
• have a history or presence of/significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
• history of deep leg vein thrombosis or a frequent appearance of deep leg vein thrombosis in first-degree relatives
• show evidence of significant active neuropsychiatric disease
• regular use of known drugs of abuse and/or show positive findings on drug screening
• show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies
• show evidence of hepatitis C and/or positive hepatitis C antibody
• show evidence of hepatitis B and/or positive hepatitis B surface antigen
• are women with a positive pregnancy test or women who are lactating
• have an average weekly alcohol intake that exceeds 21 units per week (males) or 14 units per week (females)
• had more than 1 episode of severe hypoglycemia within 6 months prior to study
• undergoing therapy for a malignancy other than basal cell or squamous cell skin cancer
• had a blood transfusion or severe blood loss within 3 months; made a blood donation within 30 days prior to study entry; or have known hemoglobinopathy, haemolytic anemia, or sickle cell anemia
• are receiving systemic glucocorticoid therapy
• have irregular sleep/wake cycle (for example, participants who sleep during the day and work during the night)
• show a history of adverse reactions to heparin, including heparin-induced thrombocytopenia
• smoke more than 10 cigarettes (or equivalent other tobacco products) per day